Developer docs
API playgroundTry for free, no card

Search company profiles

EcoR1 Capital

Full company profile

uuid0000atn

Namestring
EcoR1 Capital
Legal namestring
EcoR1 Capital, LLC
Websiteurl
ecor1cap.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

EcoR1 Capital, LLC is a privately held, biotech-focused investment advisory firm headquartered at 357 Tehama Street, Floor 3, San Francisco. Founded in 2013 by Oleg Nodelman—previously a portfolio manager at BVF Partners—the firm invests in companies across all stages of research and development, with a portfolio spanning 60–70+ biotechnology companies across oncology, immunology, genetic diseases, cell therapy, and other therapeutic areas. Its stated approach emphasizes a "four-dimensional" vetting framework centered on management quality, scientific strength, financing rationale, and patient impact, delivered through long-term partnerships rather than short-term financial engineering.

The firm operates without a unified technology product platform; its core offering is investment capital and strategic partnership provided to biotech entrepreneurs. Revenue is generated through management fees and performance fees typical of private investment funds, with fund terms offered to qualified investors through Confidential Offering Circulars or Private Offering Memoranda. The team of approximately 15 includes PhD scientists, former investment bankers, biotech operators, and dedicated legal and finance functions, and the firm maintains deep operational involvement through board seats and embedded operating partners at portfolio companies such as AnaptysBio, Zymeworks, Lakefront Biotherapeutics, Actio Biosciences, and ReCode Therapeutics. Distribution is driven entirely by direct professional relationships and co-investor syndication rather than traditional sales channels.

Short descriptiontext

EcoR1 Capital is a privately held, biotech-focused investment advisory firm founded in 2013 in San Francisco that invests across all stages of drug research and development, managing a portfolio of 60–70+ biotechnology companies for qualified investors via management and performance fees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech investment management, venture capital services, life sciences advisory, biotechnology fund management, therapeutics venture investing
Industry1 code
PRIMARYFSAAALAG
Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Biotechnology Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management Fees
TypeSubscription Recurring
Description

Generates revenue through management fees and performance fees from funds managed, typical of investment advisory firms

ecor1cap.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EcoR1 Capital, LLC is a biotech-focused investment advisory firm that manages private funds deploying capital into biotechnology companies at all stages of research and development. The firm invests in public and private life sciences companies across oncology, immunology, genetic diseases, and other therapeutic areas, providing both capital and strategic partnership through long-term relationships with biotech entrepreneurs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EcoR1 Capital LLC is a biotech-focused investment advisory firm established in 2013 that invests in companies at all stages of research and development. The firm does not offer a unified technology product platform or modules — rather, it provides investment management services and strategic partnership to biotechnology companies through its venture portfolio. The company's core offering is its investment expertise and capital deployment across a portfolio of approximately 70+ biotech companies, as evidenced by their portfolio page listing companies including Accent Therapeutics, Actio Biosciences, Affinia, Affinivax, Aktis Oncology, AlloVir, Amagma, Anagin, Arcus, Artiva, Ashvattha, Atara, Atreca, Attovia, Atyr, Avidity, BridgeBio, Cellares, Centessa, Clementia, Codiak, Collegium, Denali, Dewpoint, Diagonal Therapeutics, Editas, Eikon, ElevateBio, Epikast, Flex, Freenome, Gossamer Bio, Intellia, Kezar, KindredBio, Kronos Bio, Kumquat, Kura, Magenta, Metacrine, Morphic, Morphimmune, Nabriva, Naurex, Neogene, Neurogene, Nikang, Notch, Nurix, Nuvation, Omniox, ORIC, Paratus, Pellepharm, Peloton, Prevail, ReCode, Relay, Rubius, Sage, Scholar Rock, Scorpion, Shattuck, Silverback, Syndax, Tectonic, Terremoto, Unity, Zapprx, and others.

Product and service1 record
1Biotech Investment Management Services
CategoryBiotech-focused investment advisory services
Description

Active management of private investment funds that deploy capital into public and private biotechnology companies across all stages of research and development, spanning oncology, immunology, genetic diseases, and other therapeutic areas. Provides both capital and long-term strategic partnership to biotech entrepreneurs, offered to qualified limited partners through Confidential Offering Circulars or Private Offering Memoranda.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2025-10-09
Description

Dr. Adam Schayowitz serves as Acting Chief Development Officer at Zymeworks while continuing to serve as Operating Partner at EcoR1 Capital, demonstrating direct operational involvement with portfolio company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment146 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EcoR1 Capital

Biotechnology Investment Managementecor1cap.com

EcoR1 Capital is a privately held, biotech-focused investment advisory firm founded in 2013 in San Francisco that invests across all stages of drug research and development, managing a portfolio of 60–70+ biotechnology companies for qualified investors via management and performance fees.

What EcoR1 Capital does

EcoR1 Capital, LLC is a privately held, biotech-focused investment advisory firm headquartered at 357 Tehama Street, Floor 3, San Francisco. Founded in 2013 by Oleg Nodelman—previously a portfolio manager at BVF Partners—the firm invests in companies across all stages of research and development, with a portfolio spanning 60–70+ biotechnology companies across oncology, immunology, genetic diseases, cell therapy, and other therapeutic areas. Its stated approach emphasizes a "four-dimensional" vetting framework centered on management quality, scientific strength, financing rationale, and patient impact, delivered through long-term partnerships rather than short-term financial engineering.

The firm operates without a unified technology product platform; its core offering is investment capital and strategic partnership provided to biotech entrepreneurs. Revenue is generated through management fees and performance fees typical of private investment funds, with fund terms offered to qualified investors through Confidential Offering Circulars or Private Offering Memoranda. The team of approximately 15 includes PhD scientists, former investment bankers, biotech operators, and dedicated legal and finance functions, and the firm maintains deep operational involvement through board seats and embedded operating partners at portfolio companies such as AnaptysBio, Zymeworks, Lakefront Biotherapeutics, Actio Biosciences, and ReCode Therapeutics. Distribution is driven entirely by direct professional relationships and co-investor syndication rather than traditional sales channels.

EcoR1 Capital firmographics

Firmographics
Name
EcoR1 Capital
Legal name
EcoR1 Capital, LLC
Website
https://ecor1cap.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
EcoR1 Capital is a privately held, biotech-focused investment advisory firm founded in 2013 in San Francisco that invests across all stages of drug research and development, managing a portfolio of 60–70+ biotechnology companies for qualified investors via management and performance fees.
Ownership category
akta.pro rank

EcoR1 Capital industry classification

Industry
Product category
Biotechnology Investment Management
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAAALAG
Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure)
Financial & Insurance/Asset & Wealth Management/Asset Management — ESG/Sustainable & Impact Investing

Keywords

  • Biotech investment management
  • Venture capital services
  • Life sciences advisory
  • Biotechnology fund management
  • Therapeutics venture investing

Where EcoR1 Capital is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EcoR1 Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Investment Management Fees: Generates revenue through management fees and performance fees from funds managed, typical of investment advisory firms

Go-to-market motion1 record

Marketing channels2 records

EcoR1 Capital product offering

Product offering

Core offering

EcoR1 Capital, LLC is a biotech-focused investment advisory firm that manages private funds deploying capital into biotechnology companies at all stages of research and development. The firm invests in public and private life sciences companies across oncology, immunology, genetic diseases, and other therapeutic areas, providing both capital and strategic partnership through long-term relationships with biotech entrepreneurs.

Product overview

EcoR1 Capital LLC is a biotech-focused investment advisory firm established in 2013 that invests in companies at all stages of research and development. The firm does not offer a unified technology product platform or modules — rather, it provides investment management services and strategic partnership to biotechnology companies through its venture portfolio. The company's core offering is its investment expertise and capital deployment across a portfolio of approximately 70+ biotech companies, as evidenced by their portfolio page listing companies including Accent Therapeutics, Actio Biosciences, Affinia, Affinivax, Aktis Oncology, AlloVir, Amagma, Anagin, Arcus, Artiva, Ashvattha, Atara, Atreca, Attovia, Atyr, Avidity, BridgeBio, Cellares, Centessa, Clementia, Codiak, Collegium, Denali, Dewpoint, Diagonal Therapeutics, Editas, Eikon, ElevateBio, Epikast, Flex, Freenome, Gossamer Bio, Intellia, Kezar, KindredBio, Kronos Bio, Kumquat, Kura, Magenta, Metacrine, Morphic, Morphimmune, Nabriva, Naurex, Neogene, Neurogene, Nikang, Notch, Nurix, Nuvation, Omniox, ORIC, Paratus, Pellepharm, Peloton, Prevail, ReCode, Relay, Rubius, Sage, Scholar Rock, Scorpion, Shattuck, Silverback, Syndax, Tectonic, Terremoto, Unity, Zapprx, and others.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Investment Management Services Active management of private investment funds that deploy capital into public and private biotechnology companies across all stages of research and development, spanning oncology, immunology, genetic diseases, and other therapeutic areas. Provides both capital and long-term strategic partnership to biotech entrepreneurs, offered to qualified limited partners through Confidential Offering Circulars or Private Offering Memoranda.

Companies that use EcoR1 Capital

Customer profile

Ideal customer profiles2 records

EcoR1 Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EcoR1 Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ZymeworkscoreOthers · 9 October 2025Dr. Adam Schayowitz serves as Acting Chief Development Officer at Zymeworks while continuing to serve as Operating Partner at EcoR1 Capital, demonstrating direct operational involvement with portfolio company.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

EcoR1 Capital competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

EcoR1 Capital social profiles

Digital presence

EcoR1 Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EcoR1 Capital leadership team

Management profile

Number of profiles

Profiles15 records

EcoR1 Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EcoR1 Capital M&A and investment

M&A and investment

M&A

Investments146 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EcoR1 Capital

What does EcoR1 Capital do?

EcoR1 Capital, LLC is a biotech-focused investment advisory firm that manages private funds deploying capital into biotechnology companies at all stages of research and development. The firm invests in public and private life sciences companies across oncology, immunology, genetic diseases, and other therapeutic areas, providing both capital and strategic partnership through long-term relationships with biotech entrepreneurs.

Is EcoR1 Capital a public or private company?

EcoR1 Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was EcoR1 Capital founded?

EcoR1 Capital was founded in 2013. It employs 11 to 50 people.

Where is EcoR1 Capital based?

EcoR1 Capital is headquartered in San Francisco, United States, in the North America region.

How does EcoR1 Capital make money?

One revenue line is on record: investment Management Fees.

Does EcoR1 Capital have an API?

No public API is recorded for EcoR1 Capital.

What industry is EcoR1 Capital in?

EcoR1 Capital's product category is Biotechnology Investment Management. Its primary akta.pro industry code is FSAAALAG, Sustainable Private Markets (Impact PE/VC, Private Credit, Infrastructure). Its NAICS code is 525 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingEcoR1 Capital Reports Acquisition of $17.22 Million in AnaptysBio Common SharesAnaptysBio director Oleg Nodelman and EcoR1 Capital purchased 374,580 common shares, increasing their indirect beneficial ownership to 8,254,674 shares. The transactions were reported on November 18, 2026, via EDGAR.Pulse 2.0Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA ApprovalGossamer Bio entered a structured private placement to raise up to $250 million for seralutinib, with $150 million committed and $100 million potential from warrants. The company plans to submit an NDA in September 2026, with full funding expected if the FDA accepts the application. Financing will support development and commercialization through 2028.Investing.comAlto Neuroscience prices $100M stock offering at $26.48 By Investing.comAlto Neuroscience Inc. priced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, raising approximately $100 million in gross proceeds before deducting underwriting discounts and offering expenses. The clinical-stage biopharmaceutical company intends to use the proceeds to accelerate clinical development of ALTO-207, including conducting an additional planned Phase 3 trial as monotherapy for treatment-resistant depression, as well as for general working capital purposes. The financing was led by EcoR1 Capital with participation from new and existing healthcare-focused investors, and is expected to close on Tuesday subject to customary closing conditions.Quiver Quantitative$TRAX stock is up 39% today. Here's what we see in our data. | Quiver QuantitativeTRAX stock surged 39% on July 9, 2026, with approximately $21.8 million in trading volume, according to price data from Polygon. Insider trading activity shows one sale by CAPITAL, LLC ECOR1 of 4,705,575 shares for an estimated $65 million, while three institutional investors—FINANCIAL ENHANCEMENT GROUP LLC, GAMMA INVESTING LLC, and MASSMUTUAL PRIVATE WEALTH & TRUST, FSB—added positions in Q2 2026. Seven analysts have issued price targets for TRAX in the past six months with a median target of $40.0, ranging from $30.0 to $54.0.Investing.comEcoR1 Capital buys $4.74m in Atara Biotherapeutics stock By Investing.comEcoR1 Capital, LLC purchased 507,407 shares of Atara Biotherapeutics common stock on May 7, 2026, for approximately $4.74 million at a weighted average price of $9.35 per share, representing a premium to the current stock price of $8.84. Following the acquisition, EcoR1 Capital and its affiliates beneficially own 1,552,000 shares of Atara Biotherapeutics. Separately, Atara has been working with Pierre Fabre Pharmaceuticals and the FDA to advance tabelecleucel, including extending a $9 million milestone payment deadline to HealthCare Royalty from June 2026 to January 2028.PR NewswireImmunic Announces Closing of Oversubscribed Private Placement FinancingImmunic, Inc. announced the closing of an oversubscribed private placement financing, raising $200 million in upfront gross proceeds with potential for up to an additional $200 million from warrant exercises. The financing was led by BVF Partners L.P. and included participation from multiple institutional investors including Aberdeen Investments, Avidity Partners, EcoR1 Capital, RA Capital Management, and others. The company intends to use the proceeds to fund Phase 3 ENSURE trials in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive multiple sclerosis, and begin transitioning into a commercial organization.BenzingaImmunic Stock Jumps After Pricing $400 Million Private Placement - Immunic (NASDAQ:IMUX)Immunic Inc announced a private placement of up to $400 million, with $200 million upfront through pre-funded warrants at 87 cents each and potential additional capital if accompanying warrants are exercised. The financing was led by existing investor BVF Partners and included institutional backers OrbiMed, RA Capital, Janus Henderson, Avidity Partners and EcoR1 Capital. The new capital is expected to fund the company through late 2027 while supporting Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis, with top-line data expected by end of 2026 and a potential regulatory filing in mid-2027.Institutional InvestorWith a Thin IPO Calendar, Hedge Funds Are Zeroing In on BiopharmaWith the broader IPO calendar remaining thin in January, Aktis Oncology successfully raised $318 million by selling 17.7 million shares and saw its stock surge 24.4 percent on its first day of trading, setting an early benchmark for other biopharma issuers considering public offerings. Several hedge funds and VC firms including EcoR1 Capital (9.1 percent stake), RA Capital Management (19.2 percent in SpyGlass Pharma), and Soros Capital are materially involved as investors across these prospective issuers. Eikon Therapeutics and SpyGlass Pharma have since filed their own IPO plans, while Cormorant Asset Management's third SPAC, Helix Acquisition Corp. III, also closed an IPO raising $172.5 million, collectively signaling renewed hedge fund-backed activity in the biopharma IPO pipeline.GlobeNewswireGalapagos receives transparency notification from EcoR1 CapitalEcoR1 Capital LLC, controlled by Oleg Nodelman, notified Galapagos of its 7,094,049 voting rights, representing 10.77% of the company. The stake crossed above the 10% threshold after converting 5,873,868 ADRs into ordinary shares and acquiring additional securities.GlobeNewswireGalapagos receives transparency notification from EcoR1 CapitalEcoR1 Capital LLC, controlled by Oleg Nodelman, notified Galapagos of its 10.19% stake, crossing the 10% threshold on 10 September 2024. The stake consists of 6,713,553 voting rights, including 839,388 ordinary shares and 5,874,165 ADRs, held for clients of its funds.